Pearce Samantha 4

What Happened
Samantha Pearce, EVP and Chief Commercial Officer of Jazz Pharmaceuticals, exercised 6,907 stock options and immediately sold the resulting 6,907 shares on May 28, 2026. The exercise price was $109.45 per share (total cost $755,971) and the shares were sold in an open-market transaction at $235.41 per share for gross proceeds of $1,625,977 — a pre-tax spread of $870,006.

Key Details

• Transaction date: May 28, 2026. Form 4 filed June 1, 2026 (timely — within two business days).
• Option exercise: 6,907 shares exercised at $109.45 (total $755,971). (Transaction code M)
• Sale: 6,907 shares sold at $235.41 (gross proceeds $1,625,977). (Transaction code S)
• Derivative disposition line shows the option converted to shares (reported as $0 on derivative line).
• Shares owned after transaction: not specified in the provided excerpt.
• Footnote: Options were granted under the 2011 Equity Incentive Plan, vested over four years from March 2, 2020, and were fully vested as of March 2, 2024 (per F1).

Context

• This was an exercise followed by an immediate sale (commonly a cashless exercise), converting vested options into shares and selling them the same day.
• Sales by executives can be routine (e.g., liquidity or tax-related) and do not necessarily indicate a change in company outlook.
• Transaction codes: M = option exercise; S = open-market sale.